Cardiac remodelling is the expression of molecular, cellular and interstitial changes in response to cardiac injury, manifesting as adverse alterations in the size, shape and function of the ventricle. Several clinical studies have documented significant elevations in the levels of renin, angiotensin II (Ang II) and aldosterone attending acute myocardial infarction and/or congestive heart failure. Similar to catecholamines, markedly elevated activity of the renin-angiotensinaldosterone system (RAAS) is associated with poor prognosis. The effects of Ang II upon cardiac tissue are related to two primary receptors, Ang II type 1 (AT 1) and Ang II type 2 (AT 2 ). The AT 1 -receptor appears to mediate many of the deleterious effects of chronic RAAS activity, while the AT 2 -receptor is increasingly shown to have potential cardioprotective effects. Attenuating the deleterious effects of sustained Ang II stimulation can be achieved by direct inhibition of angiotensinconverting enzyme (ACE) and/or direct antagonism of AT receptors. ACE inhibition reduces left ventricular (LV) volumes, retards the progression of LV dilatation and hypertrophy and increases systolic function in systolic dysfunction. By blocking at the receptor level, Ang II receptor blockers (ARBs) provide an alternative and more direct approach to inhibiting the effects of Ang II; however, data relating to their effects upon ventricular remodelling, whether used in isolation or in combination with ACE inhibitors (ACE-Is), are less convincing. Data arising from several recent clinical trials suggest that simultaneous use of ACE-Is and ARBs maybe of more benefit in attenuating ventricular remodelling than either agent alone.
Introduction
Cardiac remodelling is the expression of molecular, cellular and interstitial changes in response to cardiac injury, manifesting as adverse alterations in the size, shape and function of the ventricle. 1, 2 Several factors influence this process and include haemodynamic load, neurohormonal activation, ischaemia, necrosis, and apoptosis. [3] [4] [5] Although aetiologies for cardiac injury may differ, they all share common pathways that initiate and perpetuate remodelling, the most common and well studied of which is myocardial infarction (MI). [3] [4] [5] Various autocrine, paracrine and endocrine systems are involved in the afferent signalling systems involved in cardiac remodelling. 6 Several neurohormones have pleiotropic effects upon cel-lular expression and function, including hypertrophy and fibrosis. Elevation of neurohormones has been shown to portend poor prognosis; individuals who have minimal elevation in neurohormonal activity following an infarct have been shown to have less cardiac remodelling and improved prognosis. 6 Increased activity of the following neurohormones has been well established: catecholamines, renin-angiotensin-aldosterone axis, endothelin, natriuretic peptides, prostaglandins and cytokines. [7] [8] [9] [10] [11] [12] Many of these hormonal systems are inter-linked; an aberration of one will involve adverse activity of the others and many have synergistic effects upon remodelling. Pharmacological manipulation of these complicated systems therefore has the potential to alter the remodelling process.
Of the several pharmacological approaches to ventricular remodelling, only a few have proven efficacy in attenuating and/or reversing remodelling in large-scale clinical trials.These have been: β adrenoreceptor antagonists (β-blockers), angiotensin-converting enzyme (ACE) inhibitors and aldosterone antagonists. 13 In this article, we review the molecular mechanisms of reninangiotensin-aldosterone system (RAAS) activation involved in ventricular remodelling and relate these to the potential role of angiotensin II (Ang II) receptor blockers (ARBs) in attenuating this process.
Remodelling
Ventricular remodelling begins fairly rapidly, often occurring within the first few hours following an infarct. 14 The ultimate time course for progression is influenced by several factors, such as recurrent ischaemia, neuroendocrine activation, genotype and treatment. 3 In the post-infarct setting, the degree and magnitude of remodelling has been shown to correlate with infarct size. 5 Changes in myocyte structure and function, fibroblast activity and the surrounding interstitium are fundamental to the remodelling process. Following an insult, myocyte numbers decrease, and the remaining cells undergo elongation and hypertrophy. 15, 16 Reactive changes in the interstitium include increased fibroblast and myocardial collagenase activity, which have the effect of disorganising the tissue network and/or skeleton of the myocardium, resulting in increased myocardial fibrosis and further contributing to chamber dilatation. 15 At the molecular level, many of these changes (which are still being elucidated) represent alterations in genetic programming in an attempt to preserve myocardial efficiency and energetics. 13 These include activation of foetal genes and processes not normally expressed in the adult heart (e.g. atrial natriuretic factor, β myosin heavy chain, foetal α3 subunit of the sodium pump, and several glycolytic enzymes) and repression of several adult genes (e.g. down-regulation of the β1 adrenoreceptor and reduced activity of the Ca ++ ATPase of the sarcoplasmic reticulum).The culmination of these processes produces three main histological features common to cardiac remodelling: cellular hypertrophy, myocardial fibrosis and apoptosis. 15, 16 Grossly, geometric alterations that attend remodelling include eccentric ventricular dilatation associated with increasing sphericity and larger chamber volumes. Cardiac remodelling is associated with the syndrome of heart failure, and many believe that heart failure results from decompensated cardiac remodelling. 1 Nevertheless, the relationship between cardiac remodelling and heart failure remain unclear; factors influencing this relationship are still under investigation.
Cardiac remodelling is associated with a marked increase in cardiovascular (CV) morbidity and mortality. [17] [18] [19] Both the Survival and Ventricular Enlargement (SAVE) and Studies of Left Ventricular Dysfunction (SOLVD) have clearly demonstrated that cardiac enlargement and/or progressive ventricular dilatation are independently associated with adverse CV outcomes, including CV death and heart failure. 18, 19 There is great interest in not only identifying individuals who remodel, but also in evaluating various therapies that may attenuate and/or reverse the process. 19
Renin-angiotensin-aldosterone system (RAAS)
One of the most significant products of RAAS activation is Ang II. Ang II, a potent vasoconstrictor, stimulates the formation and secretion of aldosterone from the adrenal gland, and has pleiotropic effects upon cellular growth. 20 The majority of Ang II is derived from the precursor, angiotensin I (Ang I), which originates from angiotensinogen, produced by the liver. The formation of Ang I from angiotensinogen is rate-limited by the protease, renin, which is produced by the juxtaglomerular cells of the kidney. Primary stimuli for renin secretion and RAAS activation are: impaired renal perfusion, salt depletion, and β 1 adrenergic stimulation. Ang II inhibits renin secretion, via a negative feedback loop. 21 While the majority of Ang I is converted to Ang II primarily through the activity of ACE, non-ACE pathways also exist and modulate the production of Ang II. The highest concentration of ACE exists within the pulmonary circulation; however, many studies have documented the existence of local tissue RAASs. 21 Ang II mediates its actions through G-coupled protein receptors.Ang II is involved with vascular tone and endothelial function, cardiac contractili-ty, impulse propagation and stimulates the formation and secretion of aldosterone; it has pleiotropic effects upon cellular growth and apoptosis. 22 The effects of Ang II upon cardiac tissue are related to two primary receptors,AT 1 and AT 2 .The AT 1 -receptor consists of two subtypes, AT 1 A and AT 1 B.The AT 1 A receptor appears to mediate many of the pressor and growth effects of Ang II. 22 Activation of AT 1 -receptors provokes the initiation of a variety of events, including phospholipase C activation, resulting in activation of protein kinase C and the phosphorylation of numerous proteins involved in cellular function and growth. 23 Ligand binding of AT 1 -receptors also results in their internalisation into intracellular vesicles, and these receptors appear to cycle continuously between endosomal vesicles and the plasma membrane; this does not occur with AT 2receptors, which remain fixed at the plasma membrane. Internalised Ang II (via AT 1 ) is either degraded or exerts other intracellular effects, which may affect nuclear transcription, as recent evidence has shown the existence of an Ang II nuclear binding site; 24 resulting in a host of intracellular processes and responses.
Activation of the RAAS commonly accompanies myocardial dysfunction. Several clinical studies have documented significant elevations in the levels of renin, Ang II and aldosterone attending acute MI and/or congestive heart failure. 1 Similar to catecholamines, markedly elevated activity of the RAAS is associated with poor prognosis.
AT receptors and cardiovascular disease
The cardiac effects of prolonged Ang II stimulation have been well documented and include marked cardiac hypertrophy and interstitial fibrosis. 25 It has been suggested that this receptor also mediates vasoconstriction, aldosterone secretion, and catecholamine release; all of which have been implicated in the progression of ventricular remodelling. 26 In addition, Ang II has been shown to induce apoptosis in rat ventricular myocytes. The mediator of the majority of these effects appears to be the AT 1 -receptor. 23 AT 1 knockout mice have severe cardiac developmental defects and increased mortality. 27 Interestingly, isolated AT 1 A knockout mice have been shown to display less remodelling and increased survival following acute MI. 28 Animals overexpressing AT 1 -receptors exhibit marked cardiac hypertrophy and fibrosis. 29 Human studies have also demonstrated that the AT 1 -receptor (particularly AT 1 A) is largely responsible for many of the pathological effects of Ang II. 30 These findings exemplify the importance of AT 1 -receptors in mediating cellular growth and in causing hypertrophy and fibrosis during remodelling.
Infarcted cardiac tissue demonstrates changes in AT receptor ratios and densities, with an increase in AT 2 -receptor numbers. The density of individuals with dilated cardiomyopathy or ischaemic heart disease are similarly markedly increased. 31 The role of the AT 2 -receptor is less clear. In vitro studies have documented that selective antagonism of this receptor leads to incremental signalling of the AT 1 -receptor, suggesting that the AT 2 -receptors may counteract many of the effects of the AT 1 -receptor. 32 Conversely, apoptosis has also been documented following AT 2 stimulation. 33 The AT 2 -receptor is currently regarded as having opposite effects to the AT 1 -receptor.Animal studies have revealed that stimulation of the AT 2receptor results in suppression of myocardial hypertrophy, 34 fibroblast proliferation 35 and vascular cell hyperplasia. 36 In addition, genetically engineered mice with selective deletion of the AT 2 subtype demonstrated enhanced interstitial fibrosis and left ventricular hypertrophy (LVH); the converse was the case with selective up-regulation of this receptor. Similarly,AT 2 -receptor-deleted mice appear to experience marked post-MI ventricular remodelling and reduced survival, when compared to their normal counterparts, with reductions in survival being accounted for by an overwhelming development of heart failure. 37 Overexpression of this receptor has been shown to attenuate the remodelling process in post-MI mice. 37 Whether these findings can be extrapolated to humans is still a matter of debate.
Mechanisms by which the AT 2 -receptor may be eliciting cardioprotective effects are not well understood; most data has come from studies involving animal models selectively overexpressing the AT 2 subtype. Several studies have demonstrated that AT 2 -receptor signalling is associated with enhanced production of kinins and nitric oxide (NO), 38 both of which are associated with vasorelaxation and hence afterload reduction. In addition, AT 2 -receptors are found in significant numbers in the kidney, where they are thought to contribute to natriuresis. 39 The deleterious effect of AT 2 deletion and/or AT 1 overexpression may be partly explained by adverse systemic haemodynamics, resulting in increased volume and afterload, thus accounting for many of the compensatory changes of remodelling witnessed in these animal models.
Attenuating the effects of angiotensin II
Attenuating the deleterious effects of sustained Ang II stimulation can be achieved by direct inhibition of ACE, Ang II forming chymase, and/or direct antagonism of AT receptors. There is overwhelming evidence supporting the favourable effects of ACE inhibitors (ACE-Is) in reducing adverse clinical outcomes post-MI. [40] [41] [42] Other studies have also demonstrated that ACE-Is, when compared with placebo, reduce left ventricular (LV) volumes, retard the progression of LV dilatation and hypertrophy and increase systolic function. 19 This may partially explain their proven clinical efficacy in reducing CV events post-MI and in the management of heart failure. 19 The gross bene-ficial effects of these compounds are multifactorial and include transient reductions in Ang II and aldosterone levels (both of which have direct vasoconstrictive and smooth muscle proliferative effects) and reduced degradation of bradykinin (an established vasorelaxant). Despite transient reductions in Ang II formation, chronic ACE inhibition is associated with persistent morbidity and mortality benefits.
The observation that Ang II levels appear to normalise despite chronic ACE inhibition provides a rationale for alternative methods of Ang II antagonism. By blocking angiotensin at the receptor level,ARBs provide an alternative and more direct approach to inhibiting the effect of Ang II. Potential advantages of ARBs over ACE-Is include direct and selective antagonism of the AT 1 -receptor (regardless of Ang II levels) and, possibly, a reduced side-effect profile, as AT 1 -receptor blockade is thought not to increase bradykinin levels (which are thought to mediate many of the side effects of ACE-Is).
From a clinical perspective, up until recently, all large-scale randomised clinical trials, such as The OPtimal Therapy In Myocardial infarction with the Angiotensin II Antagonist Losartan (OPTI-MAAL) in post-MI patients, Evaluation of Losartan In The Elderly II (ELITE II) and Valsartan Heart Failure Trial (Val-HEFT), in heart failure patients, have not been able to claim equivalency and/or superiority of ARBs when compared with ACE-Is in attenuating adverse cardiac outcomes. [43] [44] [45] As such, the role of ARBs in the management of heart failure and post-MI patients has mainly been restricted to those who are ACE-I intolerant.
Recently, in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) trial demonstrated an overall morbidity and mortality benefit when an ARB was added to or used in place of an ACE-I, particularly amongst individuals with systolic dysfunction. 46 The Valsartan in Acute Myocardial Infarction Trial (VALIANT) demonstrated the non-inferiority of the ARB, valsartan, to an ACE-I on clinical outcomes among a high-risk post-MI cohort. 47 Combination therapy with both ACE-I and ARB did not provide any further survival benefit, but was associated with increased side effects. 47
Angiotensin receptor blockers and remodelling
Despite the wealth of experimental evidence implicating the AT 1 -receptor as a pathogenic mediator for ventricular remodelling, animal studies have revealed conflicting results concerning AT 1 blockade in attenuating remodelling. Some studies have revealed minimal or no effects upon remodelling, 48 whilst others have documented inhibition of LVH, ventricular dilatation and collagen deposition when compared with placebo. 49 Other animal studies have suggested that the combination of AT 1 blockade and ACE inhibition may be superior to either agent alone in attenuating remodelling. In a pig model of rapid atrial pacing-induced heart failure, the combination of benzeprilat and valsartan improved cardiac output, fractional shortening, and wall stress, compared with either agent alone. 50 Large studies evaluating AT 1 blockade on remodelling effects in humans are limited and mainly involve heart failure cohorts. Important clinical studies have involved the ELITE ventricular function substudy and the Randomised Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. 51, 52 The ELITE ventricular substudy assessed changes in ventricular volumes in a subgroup of elderly patients with heart failure and/or LV function ejection fraction [EF] (<40%). 51 This was a small substudy involving a total of 29 patients being randomised to losartan or captopril; echocardiograms were obtained at baseline and at 48 months. Both treatment arms prevented LV dilatation, as evidenced by reductions in the LV end-diastolic indices at 48 months; there appeared to be greater reductions with captopril than with losartan. 51 The relationship to clinical outcomes was not outlined. Although a small study, it has documented that an ARB in the clinical arena is able to prevent remodelling.
The RESOLVD pilot study evaluated 768 patients with NYHC II-IV, who were randomised to receive candersartan, enalapril or the combination and were evaluated over a period of 43 weeks. 52 No significant differences were observed between enalapril and candersartan with respect to LVEF and ventricular volumes. However, this appears to be the first relatively large-scale study that has documented that combination therapy appeared to significantly attenuate ventricular remodelling when compared with either agent alone, 52 which also supports what has been documented in various animal models.
With proven benefit of β blockade in heart failure and post-MI, there is increasing use of 'triple' therapy with an ACE-I, β-blocker and ARB in patients with LV dysfunction and/or heart failure. This approach has been based on the argument that combined blockade of both the reninangiotensin and sympathetic nervous systems may be of greater benefit in these patients. The safety of such combination therapy had been debated previously, but large-scale trials, such as CHARM and VALIANT, have documented such regimens as being both clinically safe and efficacious. 46, 47 However, the effect upon remodelling has not been well described. In a subsequent study involving the RESOLVD cohort, the addition of metoprolol to combination therapy was also examined. 53 The use of triple therapy with an ACE-I,ARB and βblocker portrayed a trend towards greater attenuation of remodelling compared with either agent alone or combination ACE-I/ARB therapy. 53 Nevertheless, clinical studies evaluating the effects of ARBs on ventricular remodelling are quite limited. From the current information that is available, it would appear that ARBs are able to attenuate ventricular dilatation; however, their effects are modest in comparison to the established anti-remodelling effects of ACE-Is. Combination therapy with an ACE-I and ARB appears to be more beneficial than either agent alone, and supports the concept that more complete RAAS blockade at both the enzyme and receptor level should further attenuate remodelling. Although a trend towards better anti-remodelling effects is suggested with the addition of βblockers, the interaction between combination ACE inhibition/ARB with β blockade still requires further elaboration and study.
Effects of ARBs on remodelling (either in isolation or combined with ACE-Is) in the post-MI setting is limited. In an echocardiographic substudy of OPTIMAAL consisting of 225 patients, ventricular function improved with therapy with both captopril and losartan, with slightly greater benefit seen with captopril. 54 This study was limited by the small sample size, a restricted age group (>50 years or older), emphasis upon wall motion score indices rather than actual ventricular volumes, and a very short follow-up period of three months.
The VALIANT echo substudy was designed to assess the effect of treatment with an ACE-I,ARB or a combination of the two on changes in ventricular size and function in patients with left ventricular dysfunction and/or heart failure following MI. This substudy enrolled 610 patients from the main VALIANT cohort. Patients were randomised to valsartan 160 mg b.d., captopril 50 mg t.d.s., or the combination of captopril 50 mg t.d.s. plus valsartan 80 mg b.d.. Patients were studied with echocardiography at baseline, one month and 20 months. Baseline echocardiographic assessment was a potent predictor of adverse outcomes. However, there were no differences in changes in ventricular size or function in patients treated with captopril, valsartan or the combination. These data suggest that valsartan has similar effects with respect to cardiac structure and function as a dose of captopril which was previously shown to affect cardiac remodelling. 55 The interaction of aldosterone antagonists with ACE inhibition, ARB or their combination on remodelling remains to be specifically studied.
Conclusions
Current experimental evidence suggests that AT 2receptors play definitive roles in the process of ventricular remodelling. Most animal-based studies and a few human studies seem to implicate AT 1 signalling as a significant contributor to ventricular remodelling, whilst the AT 2 subtype may have protective effects -this is less clear. Intuitively, it would seem that blockade of AT 1 -receptors immediately following myocardial injury should attenuate the remodelling process. Several animal-based studies have revealed that combination therapy with AT 1 blockade and ACE inhibition seems to reduce remodelling when compared with placebo and either agent alone. Clinical studies suggest that ACE inhibition alone, ARBs alone, or their combination, have similar effects upon cardiac remodelling with the doses of drug tested thus far, suggesting redundancy in using combination therapy given semblant effects. 
